{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:45:25Z","timestamp":1779907525944,"version":"3.53.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011584","name":"Instituto Danone","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010710","name":"Dairy Farmers of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001044","name":"Dairy Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015176","name":"Flax Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015613","name":"Dow AgroSciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015175","name":"Canola Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.atherosclerosis.2020.07.028","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T11:18:22Z","timestamp":1596626302000},"page":"54-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Lomitapide for treatment of homozygous familial hypercholesterolemia: The Qu\u00e9bec experience"],"prefix":"10.1016","volume":"310","author":[{"given":"Sumayah","family":"Aljenedil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latifah","family":"Alothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre M.","family":"B\u00e9langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubin","family":"Lahijanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8414-3847","authenticated-orcid":false,"given":"Patrick","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.07.028_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2014.07.003","article-title":"What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?","volume":"15","author":"Santos","year":"2014","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.07.028_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0021-9150(99)00109-4","article-title":"Familial hypercholesterolemia. Acceptor splice site (G-->C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R(Honduras-1) [LDL-R1061(-1) G-->C]","volume":"146","author":"Yu","year":"1999","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.07.028_bib3","first-page":"1210","article-title":"Simplified Canadian definition for familial hypercholesterolemia","volume":"34","author":"Ruel","year":"2018","journal-title":"Can. J. Cardiol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2020.07.028_bib4","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"279","key":"10.1016\/j.atherosclerosis.2020.07.028_bib5","first-page":"731","article-title":"Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia","volume":"76","author":"Haitas","year":"1990","journal-title":"Q. J. Med."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2020.07.028_bib6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.07.028_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MOL.0000000000000686","article-title":"Evidence for improved survival with treatment of homozygous familial hypercholesterolemia","volume":"31","author":"Belanger","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.07.028_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.07.028_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.9.2.211","article-title":"Homozygous familial hypercholesterolemia among French Canadians in Quebec Province","volume":"9","author":"Moorjani","year":"1989","journal-title":"Arteriosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.07.028_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"issue":"32","key":"10.1016\/j.atherosclerosis.2020.07.028_bib12","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society,","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.07.028_bib13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/ATVBAHA.107.160408","article-title":"Vascular calcifications in homozygote familial hypercholesterolemia","volume":"28","author":"Awan","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2020.07.028_bib14","first-page":"1553","article-title":"Canadian cardiovascular society position statement on familial hypercholesterolemia: update 2018","volume":"34","author":"Brunham","year":"2018","journal-title":"Can. J. Cardiol."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2020.07.028_bib15","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2020.07.028_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.07.028_bib17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2017.12.008","article-title":"Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia","volume":"12","author":"Hartgers","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.07.028_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"issue":"9860","key":"10.1016\/j.atherosclerosis.2020.07.028_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"9719","key":"10.1016\/j.atherosclerosis.2020.07.028_bib20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2020.07.028_bib21","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.07.028_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MOL.0b013e32836139df","article-title":"Microsomal transfer protein inhibition in humans","volume":"24","author":"Cuchel","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2020.07.028_bib23","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1002\/humu.1380110173","article-title":"Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians","volume":"1","author":"Couture","year":"1998","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.07.028_bib24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1172\/JCI114531","article-title":"Common low-density lipoprotein receptor mutations in the French Canadian population","volume":"85","author":"Leitersdorf","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.07.028_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/humu.1380060307","article-title":"Rapid restriction fragment analysis for screening four point mutations of the low-density lipoprotein receptor gene in French Canadians","volume":"6","author":"Vohl","year":"1995","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.07.028_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jca.21406","article-title":"Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia","volume":"31","author":"Drouin-Chartier","year":"2016","journal-title":"J. Clin. Apher."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.07.028_bib27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.07.028_bib28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2020.07.028_bib29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2020.07.028_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14740338.2019.1602606","article-title":"Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia","volume":"18","author":"Khoury","year":"2019","journal-title":"Expet Opin. Drug Saf."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2020.07.028_bib31","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1194\/jlr.M300094-JLR200","article-title":"CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans","volume":"44","author":"Chandler","year":"2003","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2020.07.028_bib32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s10620-016-4037-1","article-title":"Quantitative imaging biomarkers of NAFLD","volume":"61","author":"Kinner","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2020.07.028_bib33","first-page":"1263","article-title":"2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can. J. Cardiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.07.028_bib34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacl.2019.05.002","article-title":"A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman Study,","volume":"13","author":"Stefanutti","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2020.07.028_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosissup.2017.05.006","article-title":"Current insights into the German lipoprotein apheresis registry (GLAR) - almost 5 years on","volume":"30","author":"Schettler","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.028_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","article-title":"Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017","volume":"290","author":"Pottle","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.028_bib37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2018.01.034","article-title":"A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)","volume":"270","author":"Kayikcioglu","year":"2018","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2020.07.028_bib38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.5551\/jat.RV17033","article-title":"Familial hypercholesterolemia and lipoprotein apheresis","volume":"26","author":"Makino","year":"2019","journal-title":"J. Atherosclerosis Thromb."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2020.07.028_bib39","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/2047487317730473","article-title":"The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis","volume":"24","author":"Leipold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.07.028_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J Clin Lipidol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502030410X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502030410X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:25:00Z","timestamp":1762187100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502030410X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":39,"alternative-id":["S002191502030410X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.07.028","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lomitapide for treatment of homozygous familial hypercholesterolemia: The Qu\u00e9bec experience","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}